Antiandrogenic and antimineralocorticoid health benefits of COC containing newer progestogens: dienogest and drospirenone
Metrics: PDF 1831 views | HTML 6280 views | ?
Pedro-Antonio Regidor1 and Adolf E. Schindler2
1 Exeltis West Europe & Germany, Ismaning, Germany
2 Institut für Medizinische Forschung, Essen, Germany
Pedro-Antonio Regidor, email:
Keywords: dienogest, drospirenone, therapeutics, antiandrogenic, antimineralocorticoid
Received: January 04, 2017 Accepted: March 06, 2017 Published: August 03, 2017
Data have demonstrated that COCs, besides offering a satisfactory and safe contraception, offer a variety of non-contraceptive health benefits and therapeutic positive aspects. Many prescribes and users, however, do not realize these positive aspects especially the non-contraceptive health benefits. While the contraceptive use is the primary indication for COC use for most women, these users should be advised in regard of the non-contraceptive benefits when contraception is discussed and prescribed.
Using COCs specifically for non-contraceptive indications is an off-label use in many clinical situations (only some exceptions as e.g. acne vulgaris in some countries are allowed clinical entities for the use of these drugs). Therefore, appropriate discussions with the patient regarding this fact should performed and documented by the prescribing physicians.
Independent of the off-label situation, COCs containing the newer progestogens dienogest and drospirenone with their antiandrogenic and antimineralocorticoid health benefits play an important role in the management of many diseases and their use should therefore be considered by clinician’s.
This review will focus on the effects of these COCs on the endometrium, the skin, the fat tissue and the premenstrual syndrome.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.